145 related articles for article (PubMed ID: 25747449)
1. A ligand-based virtual screening approach to identify small molecules as HERG channel activators.
Giacomini E; Buonfiglio R; Masetti M; Wang Y; Tseng GN; Roberti M; Recanatini M
Comb Chem High Throughput Screen; 2015; 18(3):269-80. PubMed ID: 25747449
[TBL] [Abstract][Full Text] [Related]
2. Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
Kratz JM; Schuster D; Edtbauer M; Saxena P; Mair CE; Kirchebner J; Matuszczak B; Baburin I; Hering S; Rollinger JM
J Chem Inf Model; 2014 Oct; 54(10):2887-901. PubMed ID: 25148533
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
4. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
5. Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
Du F; Babcock JJ; Yu H; Zou B; Li M
PLoS One; 2015; 10(2):e0118324. PubMed ID: 25700001
[TBL] [Abstract][Full Text] [Related]
6. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
7. Revealing the structural basis of action of hERG potassium channel activators and blockers.
Perry M; Sanguinetti M; Mitcheson J
J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767
[TBL] [Abstract][Full Text] [Related]
8. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
9. An automated docking protocol for hERG channel blockers.
Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
[TBL] [Abstract][Full Text] [Related]
10. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
11. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
[TBL] [Abstract][Full Text] [Related]
12. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
13. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Narayana Moorthy NS; Ramos MJ; Fernandes PA
Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
[TBL] [Abstract][Full Text] [Related]
14. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
15. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
16. Ligand structural aspects of hERG channel blockade.
Aronov AM
Curr Top Med Chem; 2008; 8(13):1113-27. PubMed ID: 18782007
[TBL] [Abstract][Full Text] [Related]
17. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
Thai KM; Ecker GF
Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
[TBL] [Abstract][Full Text] [Related]
18. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Yu Z; Klaasse E; Heitman LH; Ijzerman AP
Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore modeling for hERG channel facilitation.
Yamakawa Y; Furutani K; Inanobe A; Ohno Y; Kurachi Y
Biochem Biophys Res Commun; 2012 Feb; 418(1):161-6. PubMed ID: 22244872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
